Latest Content

In today's Pharmaceutical Executive Daily, a commentary examines why fragmented software tooling causes scientific judgment to get lost across the biologics R&D pipeline, Replimune shares crash nearly 32 percent after FDA reviewers raise concerns about its melanoma therapy, and FDA approves Viatris's Gwyn Lo as a new once-weekly contraceptive patch.

An FDA advisory panel voted to recommend six of seven unapproved peptides for compounding access, raising concerns about its newly appointed members.

FDA has approved Viatris' Gwyn Lo as a once-weekly low-dose estrogen contraceptive patch, offering women with a BMI below 30 a non-invasive hormonal contraception option.

Replimune shares fell nearly 32% after FDA staff reviewers raised concerns that its lead melanoma therapy RP1 lacks clear evidence of systemic efficacy.

The shift from looking at lots of possibilities to focusing on specific ones in a drug discovery pipeline is why traditional pipelines don’t work well.

LucyRx’s chief commercial officer explains why the traditional two-bucket approach to GLP-1 coverage, which focuses on diabetes and weight loss, leaves high-risk populations without access.

John Stanford, executive director at Incubate, discusses how China's two decades of biotech investment are paying off.

In this episode, Ron Lanton argues that healthcare's next constraint isn't capital or technology but rather people.

In today's Pharmaceutical Executive Daily, BioMarin and n-Lorem Foundation partner on the first disease-targeted therapy for the recently identified ReNU syndrome, a trio of biotech financings advance rare disease, sleep apnea, and oncology pipelines, and a Wharton professor offers career advice for MBA graduates navigating an AI-reshaped job market.

Oak Hill Bio secures $175 million through a SPAC combination with RA Capital, Apnimed set terms for a $150 million IPO, and CORE Biomedicine closes a $21 million Series A.

A career Q&A with Professor Patrick T. Harker, B.S., M.S., Ph.D., of the Wharton School of the University of Pennsylvania.

TruTechnologies chairman and co-founder argues that while Operation TrialBlazer is directionally correct in targeting regulatory friction, it misses the larger problem.

In today's Pharmaceutical Executive Daily, FDA approves Otsuka's Simtriyo as the first NDSRI treatment for ADHD, argenx agrees to acquire Forte Biosciences for approximately $2.2 billion, and an AbbVie neuroscience researcher discusses the shift from symptom management to disease modification in Parkinson's research.